The idea for Dyno Therapeutics Inc.’s CapsidMap platform for developing novel capsids for adeno-associated virus (AAV) vectors came to fruition after CEO and co-founder Eric Kelsic joined the Harvard University lab of George Church as a post-doc in 2015. The company officially launched in 2018 with $9m in seed funding and now it is emerging from stealth mode with gene therapy partnerships that Dyno says are worth up to $2bn in upfront payments, research funding and milestone fees.
Those collaborations announced on 11 May give Novartis AG and Sarepta Therapeutics Inc. access to CapsidMap, which combines...








